AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $177,030 | +8.3% | 3,500 | 0.0% | 0.01% | +14.3% |
Q2 2023 | $163,415 | +22.0% | 3,500 | 0.0% | 0.01% | +16.7% |
Q1 2023 | $133,910 | +69644.8% | 3,500 | 0.0% | 0.01% | -33.3% |
Q4 2022 | $192 | -99.8% | 3,500 | 0.0% | 0.01% | +50.0% |
Q3 2022 | $119,000 | +260.6% | 3,500 | 0.0% | 0.01% | +500.0% |
Q2 2022 | $33,000 | -34.0% | 3,500 | 0.0% | 0.00% | -50.0% |
Q1 2022 | $50,000 | -32.4% | 3,500 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $74,000 | – | 3,500 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |